The year in charts

Tuesday, April 23, 2024 @ 11:00 am

Capital investments in Swiss biotech companies 2014 -2023

Private & Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2021-2023

Total Swiss Biotech Companies

Note: The 2023 data in above tables is based on information that was available up until March 31, 2024. At this time, some of the companies had not yet disclosed their financial figures for 2023. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2023)

Revenues, R&D expenses, profit/loss, liquidity 2021-2023

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2021-2023

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2014-2023

Number of Swiss biotech employees 2021-2023

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

LimmaTech appoints Staph Leavenworth Bakali as Chairman of the Board

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience in the life science and healthcare industries.
July 1, 2024

Newron flash update “A pivotal year” - potential of schizophrenia drug

June 27, 2024

Ymmunobio and EVIIVE: Collaboration to develop advanced liquid biopsy for cancer patients

Ymmunobio and EVIIVE are pleased to announce their strategic collaboration to develop an innovative liquid biopsy technology utilizing extracellular vesicles (EVs). This partnership marks a significant advancement in precision medicine, aiming to enhance disease detection and patient monitoring accuracy and efficacy.
June 24, 2024

iOnctura: EUR 80 million series B financing to progress pipeline through Phase II trials

Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications
June 20, 2024

NXI Therapeutics: Extending pre-seed financing to CHF 3.5 million

Kickfund joins group of investors including JFG Life Sciences Foundation, BaseLaunch, and Venture Kick
June 18, 2024

The year in charts

Capital investments in Swiss biotech companies 2014 -2023

Revenues, R&D expenses, profit/loss, liquidity 2021-2023

Revenues, R&D expenses, profit/loss, liquidity 2021-2023

Revenues, R&D expenses, profit/loss, liquidity 2021-2023

Number of biotech companies in Switzerland 2014-2023

Number of Swiss biotech employees 2021-2023

Tags

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

LimmaTech appoints Staph Leavenworth Bakali as Chairman of the Board

Newron flash update “A pivotal year” - potential of schizophrenia drug

Ymmunobio and EVIIVE: Collaboration to develop advanced liquid biopsy for cancer patients

iOnctura: EUR 80 million series B financing to progress pipeline through Phase II trials

NXI Therapeutics: Extending pre-seed financing to CHF 3.5 million